

## Particular considerations to take into account as part of geriatric palliative care

Version 28 – 28 March 2020

This text is an addendum to the recommendations issued by the SFAP (French Counselling and Palliative Care Society - <http://www.sfap.org/actualite/outils-et-ressources-soins-palliatifs-et-covid-19>) and the French College of Palliative Care. We feel it necessary to insist on the following points concerning Palliative Care for the geriatric population:

### ETHICAL CONSIDERATIONS

- The commitment level for care and whether the patient is to be resuscitated should be included in each patient's file. This should guide procedures following the patient's admission, with reassessments made on the patient's clinical conditions. Decisions not to resuscitate are subject to an order from the College, which should be included in the patient's case file.
- The patient and their loved ones should be interviewed for advance instructions, which should be included in the case file (cf. the Covid-19 resuscitation ethics RPMO document, COVIPAL document, etc.)
- It is also crucial to keep family members up-to-date on the patient's clinical condition and palliative care given.

### PRACTICAL THERAPEUTIC MEASURES

- **Make sure teams have access to drugs within each care unit!**
- **Recommended doses for young adults should be reduced as a general rule**, per those protocols put forward by the SFAP.
- **Recommendations for combining drugs within a single drum**, as issued by the SFAP, **are valid for Geriatric use.**
- **Dose regimes for the most common conditions**
  - The therapeutic treatments set out below **should be given priority based on those recommendations in place and drug availability within services.**

| BREATHLESSNESS   | ANXIETY  |
|--|--|
| <p><b>- MORPHINE:</b><br/>Bolus: 2 mg intravenously (IV) or 3 mg subcutaneously<br/>SC Baseline dose: 15 mg IV every 24 hours<br/>20 mg SC every 24 hours<br/>Orally: 5 mg bolus then 30 mg daily (15 mg treatments every 12 hours)</p> <p><b>- OXYCODONE:</b><br/>IV or SC: 2 mg bolus then 0.4 mg per hour<br/>Orally: 5 mg bolus then 20 mg daily (10 mg treatments every 12 hours)</p> <p><b>- SUFENTANIL:</b><br/>IV or SC: 4 µg bolus then 30 µg IVSE or ESSC</p> <p><b>- TRAMADOL</b> subcutaneously<br/>This should only be given in the absence of all of the other drugs listed above!<br/>50 mg bolus then 300 mg every 24 hours<br/>Can be increased up to 600 mg every 24 hours</p> | <p><b>- MIDAZOLAM:</b><br/>Bolus: 1 mg IV or SC<br/>then 10 mg IVSE or ESSC every 24 hours</p> <p><b>- CLONAZEPAM:</b><br/>0.5 mg SC or IV bolus twice every 24 hours</p> <p><b>- DIAZEPAM</b> (do not mix with other products)<br/>5 mg IV bolus or 10 mg SC bolus (never to be given on continuous drip or ESIV), max 10 mg every 24 hours</p> <p><b>- CHLORPROMAZINE:</b><br/>25 mg SC or IV bolus<br/>then 100 mg every 24 hours up to 300 mg every 24 hours (on continuous ESIV or ESSC)</p> <p><b>- CLORAZEPATE:</b><br/>40 mg IV or SC bolus<br/>then 80 mg ESIV every 24 hours or 40 mg SC twice every 24 hours (no ESSC!)</p> <p><b>- Intra-rectal DIAZEPAM:</b><br/>(Note no recommendations exist for adults, with even less available for elderly patients)<br/>5 mg bolus (in a syringe for rectal injection), maximum four times daily</p> |

### RESPIRATORY DISTRESS

**Recommended SFAP doses are valid for this emergency situation.**

They have been summarised in the tables below: **table 1 is for initial care and table 2 contains dose amounts in the event initial care does not work.**

**Table 1: initial care for respiratory distress**

|                           | IV then ES | SC then ES   | IV then drip | SC then drip | Discontinue SC                         |
|---------------------------|------------|--------------|--------------|--------------|--|
| <b>Morphine bolus</b>     | 3 mg       | 7 mg         | 3 mg         | 7 mg         | 7 mg                                   |
| <b>Midazolam bolus</b>    | 2 mg       | 3 mg         | 2 mg         | 3 mg         | 3 mg                                   |
| <b>Clonazepam bolus</b>   | 0.5 mg     | 0.5 mg       | 0.5 mg       | 0.5 mg       | 0.5 mg                                 |
| <b>Clorazepate bolus:</b> | 40 mg      | 40 mg        | 40 mg        | 40 mg        | 40 mg                                  |
| <b>Morphine relays</b>    | 1.5 mg/h   | 3 mg/h       | 30 mg/24h    | 70 mg/24h    | Two or three times daily, where needed |
| <b>Midazolam relays</b>   | 2 mg/h     | 3 mg/h       | 50 mg/24h    | 80 mg/24h    |  |
| <b>Clonazepam relays</b>  | 2 mg/24h   | 2 mg/24h     | 2 mg/24h     | 2 mg/24h     |  |
| <b>Clorazepate relays</b> | 80 mg/24h  | 40 mg 2x/day | 80 mg/24h    | 40 mg 2x/day |  |

*IV = intravenously; SC = subcutaneously; ES = electrical syringe*

*Drip = basic drip with 250 or 500 cc fluids for 24 hours.*

*Boluses are given as initial treatment and then whenever needed.*

\* Clorazepate (Tranxene) does not do well in SC drips, so give 40 mg as SC bolus every 12 hours.

**Table 2: Care procedures for respiratory distress if Table 1 doses prove ineffective**

|                           | IV then ES | SC then ES        | IV then drip | SC then drip      | Discontinue SC                         |
|---------------------------|------------|-------------------|--------------|-------------------|--|
| <b>Morphine bolus</b>     | 7 mg       | 15 mg             | 7 mg         | 15 mg             | 10 mg                                  |
| <b>Midazolam bolus</b>    | 3 mg       | 7 mg              | 3 mg         | 7 mg              | 10 mg                                  |
| <b>Bolus clonazepam</b>   | 1.5 mg     | 1.5 mg            | 1.5 mg       | 1.5 mg            | 1.5 mg                                 |
| <b>Clorazepate bolus:</b> | 80 mg      | 80 mg             | 80 mg        | 80 mg             | 80 mg                                  |
| <b>Morphine relays</b>    | 3 mg/h     | 6 mg/h            | 70 mg/24h    | 140 mg/24h        | Two or three times daily, where needed |
| <b>Midazolam relays</b>   | 4 mg/h     | 7 mg/h            | 100 mg/24h   | 200 mg/24h        |  |
| <b>Clonazepam relays</b>  | 4 mg/24h   | 4 mg/24h          | 4 mg/24h     | 4 mg/24h          |  |
| <b>Clorazepate relays</b> | 160 mg/24h | 80 mg twice daily | 160 mg/24h   | 80 mg twice daily |  |

*IV = intravenously; SC = subcutaneously; ES = electrical syringe*

*Drip = basic drip with 250 or 500 cc fluids for 24 hours.*

*Boluses are given as initial treatment and then whenever needed.*

\* Clorazepate (Tranxene) does not do well in SC drips, so give 80 mg as SC bolus every 12 hours.

**If treatment still fails**, add the following to the SC 24-hour drip/TVKO to keep veins open:

50 mg cyamemazine or 50 mg levomepromazine or 25 mg chlorpromazine

## FOR VOMITING

### HALOPERIDOL:

- 0.5 to 1 mg SC three times daily up to 5 mg SC three times daily or 1 mg IV (or 10 drops)

### ONDANSETRON:

- Apply 8 mg orally dispersible film up to three times daily if patient's liver function preserved
- Intravenously or subcutaneously: One 8 mg ampoule over 15 minutes every eight hours maximum. For patients with liver disorders reduce to 8 mg every hour orally or IV.

## CONFUSION

**MIDAZOLAM** 0.05 mg/kg SC bolus prior to care: the most satisfying option, with half an ampoule of HALDOL SC if patient's weight is over 40 kg.

## GASTRO-INTESTINAL OBSTRUCTION

**SCOBUREN** (1 mg per kg daily) and **SCOPOLAMINE** (0.05 mg per kg daily) doses identical to those prescribed for adults (give priority to Scoburen over scopolamine so as to limit major atropinine side effects!).

## ADDITIONAL MEASURES

---

Keep good geriatric practice in mind:

- take note of globus and faecaloma, whether the patient is uncomfortable and likely to be easily confused
- Non-medical anti-anxiety measures: having a light in the room, fit hearing prosthetics and glasses as soon as possible, telephone contact with loved ones where possible, etc.
- Mouthwash (use eye guards and an FFP2 mask as there is risk of sputum or cough), oxygen therapy adapted to patient's needs (careful as over 6 l/mn creates risk of virus nebulisation, so caregivers should wear an FFP2 mask)

---

**Author and co-ordinator:** Virginie Fossey-Diaz

**Contributors:** I. Hardouin, J. Chopart, S. Lefebvre Chapiro, M. Piccoli

---